Biotech Firm MIP Discovery Announces New Name and Logo

MIP Discovery has announced that it is rebranding to “Tozaro”.

A specialist in the cell and gene therapy (CGT) bioprocessing sector, the British firm’s new look comes after its completion of a £7M Series A funding round earlier in the year.

The refresh also comes at a time when the company is refocusing its mission to improve downstream processing within the CGT sector by helping to transform the development and manufacture of what are called “viral vectors”.

The latter are harmless viruses that are used to deliver genetic material into target cells.

“The promise of cell and gene therapies is being constrained by the high cost in producing treatments using methods that are inefficient and cumbersome. Tozaro’s novel approach to building reagents for viral vector manufacturing can change this,” explains Dr. Mike Evans, chair of the board at Tozaro.

Adding: “The rebrand, including a change of name to Tozaro, aligns with our ongoing commitment to growth and focus on developing novel solutions that will enable widespread adoption of next-generation therapies.”

Source: Tozaro